Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma
NCT01034553Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2010
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alisertib in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoints: Dose-limiting Toxicity at 28 days and Overall Response Rate. Started Feb 2010; status: completed.
02
Drugs
alisertib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01034553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01034553.